Travere Therapeutics (TVTX) Tops Q4 EPS by 212c

Travere Therapeutics (NASDAQ: TVTX) reported Q4 EPS of $0.94, $2.12 better than the analyst estimate of ($1.18). Revenue for the quarter came in at $45.05 million versus the consensus estimate of $41.68 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Nike names former Pfizer CFO David Denton as new finance chief
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook